Fig. 5

BDNF silencing reversed the protection of dexmedetomidine pretreatment on ropivacaine-induced neurotoxicity. si-BDNF-1 and si-BDNF-2 were transfected into HT22 and SH-SY5Y cells, with si-NC as negative control. A-B Transfection efficiency was measured using RT-qPCR and Western blot. si-BDNF-1 with a better silencing effect was selected for combined experiment with Dex-pretreated cells. C Cell viability was measured using CCK-8 assay. D LDH release was measured using LDH detection kit. E Apoptosis was measured using flow cytometry. The cell experiment was repeated 3 times independently. Data are presented as mean ± standard deviation. Data in panel C were analyzed using two-way ANOVA, and data in panels A-B/D-E were analyzed using one-way ANOVA, followed by Tukey's multiple comparisons test, ^&p < 0.05, compared with the Ropi + DEX group, ^*p < 0.05